Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 6/20 | 0.48 |
| ▸ | RAB9A | P51151 | 5/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | HPGD | P15428 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | GLA | P06280 | 1/20 | 0.48 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.48 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.48 |
| ▸ | RELA | Q04206 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | CNR1 | P21554 | 2/20 | 0.47 |
| ▸ | CNR2 | P34972 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | F2 | P00734 | 1/20 | 0.43 |
| ▸ | HSPD1 | P10809 | 1/20 | 0.43 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2688761 | 0.92 | NPC1 (0.46) | NPC1RAB9AALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL2688404 | 0.88 | MET (0.43) | NPC1RAB9AALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL2687682 | 0.86 | CNR1 (0.44) | ALDH1A1HPGDSMN1; SMN2HSD17B10KDM4E | |
| SCHEMBL2688954 | 0.85 | NPC1 (0.49) | NPC1RAB9AALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL2688587 | 0.83 | CYP11B2 (0.42) | NPC1RAB9AALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL2686059 | 0.83 | OPRM1 (0.43) | NPC1RAB9AALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL2688684 | 0.83 | MET (0.44) | NPC1RAB9AALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL2686700 | 0.83 | CYP11B2 (0.57) | NPC1RAB9AALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL10219917 | 0.82 | MET (0.43) | NPC1RAB9AALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL2686461 | 0.81 | MET (0.41) | NPC1RAB9AALDH1A1HPGDSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8829035-B2 | Agent for treatment or prevention of diseases associated with activity of neurotrophic factors | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2014-09-09 | — | — | US | disclosed |
| US-8829035-B2 | Agent for treatment or prevention of diseases associated with activity of neurotrophic factors | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2014-09-09 | — | — | US | disclosed |
| US-8829035-B2 | Agent for treatment or prevention of diseases associated with activity of neurotrophic factors | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2014-09-09 | — | — | US | disclosed |
| EP-2436683-B1 | AGENT FOR TREATMENT OR PREVENTION OF DISEASES ASSOCIATED WITH ACTIVITY OF NEUROTROPHIC FACTORS | SUMITOMO CHEMICAL CO (JP) | 2014-05-14 | — | — | EP | disclosed |
| US-20120115856-A1 | AGENT FOR TREATMENT OR PREVENTION OF DISEASES ASSOCIATED WITH ACTIVITY OF NEUROTROPHIC FACTORS | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2012-05-10 | — | — | US | disclosed |
| US-20120115856-A1 | AGENT FOR TREATMENT OR PREVENTION OF DISEASES ASSOCIATED WITH ACTIVITY OF NEUROTROPHIC FACTORS | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2012-05-10 | — | — | US | disclosed |
| US-20120115856-A1 | AGENT FOR TREATMENT OR PREVENTION OF DISEASES ASSOCIATED WITH ACTIVITY OF NEUROTROPHIC FACTORS | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2012-05-10 | — | — | US | disclosed |
| WO-2010137349-A1 | AGENT FOR TREATMENT OR PREVENTION OF DISEASES ASSOCIATED WITH ACTIVITY OF NEUROTROPHIC FACTORS | 住友化学株式会社 (JP) | 2010-12-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120115856-A1 | AGENT FOR TREATMENT OR PREVENTION OF DISEASES ASSOCIATED WITH ACTIVITY OF NEUROTROPHIC FACTORS | BDNF, NGF, NTRK2 | NPC1 525/4885RAB9A 2914/4885ALDH1A1 1772/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.